Skip to the beginning of the images gallery

soticlestat , Cholesterol 24-hydroxylase inhibitor, CAS No.1429505-03-2, Cholesterol 24-hydroxylase inhibitor

Moligand™

≥98%

CAS#: 1429505-03-2
Formula: C₂₃H₂₃N₃O₂
Molecular Weight: 373.45
PubChem CID: 73437845

Item Number

S613661

Grouped product items
SKU	Size	Availability	Price
S613661-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$139.90
S613661-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$239.90
S613661-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$469.90
S613661-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$679.90
S613661-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$989.90

View related series

CYP46A1 Inhibitor

Basic Description

Synonyms	OV935 \| OV-935 \| [2,4'-bipyridin]-3-yl(4-benzyl-4-hydroxypiperidin-1-yl)methanone \| 1766MU795L \| Soticlestat [USAN:INN] \| 1429505-03-2 \| Soticlestat (USAN) \| (4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone \| TAK935 \| TAK-935 \| Sot
Specifications & Purity	Moligand™, ≥98%
Biochemical and Physiological Mechanisms	Soticlestat is a first-in-class, potent, selective cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research.
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Cholesterol 24-hydroxylase inhibitor

Associated Targets(Human)

CYP46A1 Tchem Cholesterol 24-hydroxylase (0 Activities)

Discover Target: CYP46A1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CYP2C8 Tchem Cytochrome P450 2C8 (1492 Activities)

Discover Target: CYP2C8

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP2D6 Tclin Cytochrome P450 2D6 (33882 Activities)

Discover Target: CYP2D6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP1A2 Tchem Cytochrome P450 1A2 (26471 Activities)

Discover Target: CYP1A2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP2C9 Tchem Cytochrome P450 2C9 (32119 Activities)

Discover Target: CYP2C9

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP2C19 Tchem Cytochrome P450 2C19 (29246 Activities)

Discover Target: CYP2C19

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)

Discover Target: CYP3A4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP46A1 Tchem Cholesterol 24-hydroxylase (289 Activities)

Discover Target: CYP46A1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Names and Identifiers

IUPAC Name	(4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone
INCHI	InChI=1S/C23H23N3O2/c27-22(20-7-4-12-25-21(20)19-8-13-24-14-9-19)26-15-10-23(28,11-16-26)17-18-5-2-1-3-6-18/h1-9,12-14,28H,10-11,15-17H2
InChi Key	XKUZMIUSBMCVPP-UHFFFAOYSA-N
Canonical SMILES	C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
Isomeric SMILES	C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
Alternate CAS	1429505-03-2
PubChem CID	73437845
MeSH Entry Terms	(4-Benzyl-4-hydroxy-1-piperidinyl)(2,4'-bipyridin-3-yl)methanone;OV-935;OV935;soticlestat
Molecular Weight	373.45

CAS Registry No.

PubChem CID

ChEMBL Ligand

RCSB PDB Ligand

References

1. Miziak B, Czuczwar S. (2020) Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome.. Expert Opin Drug Discov, 129 (3): (1-15). [PMID:33275464]
2. Strzelczyk A, Schubert-Bast S. (2021) Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.. CNS Drugs, 35 (1): (61-83). [PMID:33479851]
3. Wang S, Chen G, Merlo Pich E, Affinito J, Cwik M, Faessel H. (2021) Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.. Br J Clin Pharmacol, 129 (3): (589-97). [PMID:33837574]
4. Strzelczyk A, Schubert-Bast S. (2020) Therapeutic advances in Dravet syndrome: a targeted literature review.. Expert Rev Neurother, 20 (10): (1065-1079). [PMID:32799683]
5. Nishi T, Kondo S, Miyamoto M, Watanabe S, Hasegawa S, Kondo S, Yano J, Watanabe E, Ishi T, Yoshikawa M et al.. (2020) Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice.. Sci Rep, 10 (1): (17081). [PMID:33051477]
6. Perry MS. (2020) New and Emerging Medications for Treatment of Pediatric Epilepsy.. Pediatr Neurol, 107 (3): (24-27). [PMID:31980296]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

soticlestat , Cholesterol 24-hydroxylase inhibitor, CAS No.1429505-03-2, Cholesterol 24-hydroxylase inhibitor

Basic Description

Product Properties

Associated Targets(Human)

Associated Targets(non-human)

Names and Identifiers

Database links

Certificates

Certificate of Analysis(COA)

Related Documents

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator